PAR04-122 Extramural Research Facilities Construction C*

PAR04-122 校外研究设施建设 C*

• 批准号: 7001833
• 负责人: ALLEN M. SPIEGEL
• 金额: $ 400万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-22 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7001833
• 关键词: biomedical facility; building /facility design /renovation; emerging infectious disease

DESCRIPTION (provided by applicant): Albert Einstein College of Medicine of Yeshiva University has begun construction of the Price Center for Genetic and Translational Medicine (CGTM) and seeks NIH/NCRR support for completion of 26,509 gross square feet of uninhabited shell space on the CGTM 5th floor. This floor will house the new Institute of Infectious Diseases (IID) comprising laboratories and shared resources and addressing risks of emerging disease and biological warfare. The application'of gene-based approaches to drug development will be fostered by an on-site chemical genomics facility. The IID construction plan will achieve 6 major objectives by providing: 1) Laboratories for experiments using avirulent mycobacteria as a delivery vector for immunization against other pathogens; 2) A Biosafety Level 3 facility including an area for animal experiments on aerosolized Mycobacterium tuberculosis (M.tb), and other pathogens requiring such containment; 3) Laboratories to study the mechanism of monoclonal antibody protection for treatment or protection against virulent M.tb and Bacillus anthracis, 4) Laboratories to study the pathogenesis and role of melanin in the virulence of Cryptococcus neoformans; 5) A high throughput chemical genomics facility for drug discovery using novel enzymatic pathways; and 6) Bioinformatics expertise to collaborate on experiments involving the genetics of microorganisms and host response genes. The consolidation of several outstanding groups of infectious disease investigators into larger and improved facilities will offer opportunity for synergistic expansion and advance understanding of microbial pathogenesis and spur the development of novel therapies. These goals are directly relevant to critical, unresolved health issues in the United States.

描述（由申请人提供）： 叶史瓦大学阿尔伯特·爱因斯坦医学院已经开始建设遗传和转化医学价格中心（CGTM），并寻求NIH/NCRR支持在CGTM 5楼完成26，509平方英尺的无人居住的外壳空间。该楼层将容纳新的传染病研究所（IID），包括实验室和共享资源，并应对新出现的疾病和生物战的风险。基于基因的药物开发方法的应用将由现场化学基因组学设施促进。 IID建设计划将实现6个主要目标，提供： 1)使用无毒分枝杆菌作为针对其他病原体的免疫接种载体的实验室; 2)一个生物安全三级设施，包括一个对雾化结核分枝杆菌和其他需要进行这种隔离的病原体进行动物实验的区域; 3)实验室研究单克隆抗体保护机制，以治疗或保护免受有毒的结核分枝杆菌和炭疽杆菌， 4)实验室研究致病机制和黑色素在新型隐球菌毒力中的作用; 5)一个高通量的化学基因组学设施，用于使用新型酶途径的药物发现;以及 6)生物信息学专业知识，在涉及微生物遗传学和宿主反应基因的实验中进行合作。 将几个杰出的传染病研究小组合并为更大和更好的设施将为协同扩展和促进对微生物发病机制的理解提供机会，并刺激新疗法的开发。这些目标与美国尚未解决的关键健康问题直接相关。